Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

17 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effect of adjuvant radiotherapy treatment center volume on overall survival.
Philips R, Martin D, Eskander A, Schord J, Brown N, Zhao S, Brock G, Kumar B, Carrau R, Ozer E, Agrawal A, Kang SY, Rocco JW, Schuller D, Ali S, Blakaj D, Bhatt A, Grecula J, Teknos T, Diavolitsis V, Old M. Philips R, et al. Among authors: diavolitsis v. Oral Oncol. 2018 Mar;78:46-51. doi: 10.1016/j.oraloncology.2018.01.004. Epub 2018 Jan 20. Oral Oncol. 2018. PMID: 29496057 Free PMC article.
Clinical outcomes and prognostic factors in cisplatin versus cetuximab chemoradiation for locally advanced p16 positive oropharyngeal carcinoma.
Barney CL, Walston S, Zamora P, Healy EH, Nolan N, Diavolitsis VM, Neki A, Rupert R, Savvides P, Agrawal A, Old M, Ozer E, Carrau R, Kang S, Rocco J, Teknos T, Grecula JC, Wobb J, Mitchell D, Blakaj D, Bhatt AD. Barney CL, et al. Among authors: diavolitsis vm. Oral Oncol. 2018 Apr;79:9-14. doi: 10.1016/j.oraloncology.2018.02.001. Epub 2018 Feb 12. Oral Oncol. 2018. PMID: 29598954
A phase 1 trial of Vorinostat in combination with concurrent chemoradiation therapy in the treatment of advanced staged head and neck squamous cell carcinoma.
Teknos TN, Grecula J, Agrawal A, Old MO, Ozer E, Carrau R, Kang S, Rocco J, Blakaj D, Diavolitsis V, Kumar B, Kumar P, Pan Q, Palettas M, Wei L, Baiocchi R, Savvides P. Teknos TN, et al. Among authors: diavolitsis v. Invest New Drugs. 2019 Aug;37(4):702-710. doi: 10.1007/s10637-018-0696-4. Epub 2018 Dec 19. Invest New Drugs. 2019. PMID: 30569244 Clinical Trial.
The role of adjuvant radiation in endometrial cancer.
Diavolitsis V, Boyle J, Singh DK, Small W Jr. Diavolitsis V, et al. Oncology (Williston Park). 2009 Apr 15;23(4):342-9. Oncology (Williston Park). 2009. PMID: 19476264 Free article. Review.
Platinum-based regimens versus cetuximab in definitive chemoradiation for human papillomavirus-unrelated head and neck cancer.
Beckham TH, Barney C, Healy E, Wolfe AR, Branstetter A, Yaney A, Riaz N, McBride SM, Tsai CJ, Kang J, Yu Y, Chen L, Sherman E, Dunn L, Pfister DG, Tan J, Rupert R, Bonomi M, Zhang Z, Lobaugh SM, Grecula JC, Mitchell DL, Wobb JL, Miller ED, Blakaj DM, Diavolitsis VM, Lee N, Bhatt AD. Beckham TH, et al. Among authors: diavolitsis vm. Int J Cancer. 2020 Jul 1;147(1):107-115. doi: 10.1002/ijc.32736. Epub 2019 Nov 11. Int J Cancer. 2020. PMID: 31609479
Primary vs nodal site PET/CT response as a prognostic marker in oropharyngeal squamous cell carcinoma treated with intensity-modulated radiation therapy.
Eckstein JM, Nolan N, Healy E, Wright CL, Jain A, Barney CL, Washington I, McElroy JP, Grecula JC, Wobb JL, Mitchell DL, Miller E, Gamez M, Blakaj D, Diavolitsis V, Bhatt A. Eckstein JM, et al. Among authors: diavolitsis v. Head Neck. 2020 Sep;42(9):2405-2413. doi: 10.1002/hed.26242. Epub 2020 May 11. Head Neck. 2020. PMID: 32391626
17 results